UK markets open in 9 minutes

Bluejay Diagnostics, Inc. (BJDX)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
0.5201-0.0309 (-5.61%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.5510
Open0.5410
Bid0.4926 x 100
Ask0.5875 x 100
Day's range0.5005 - 0.5838
52-week range0.3900 - 13.9800
Volume27,287
Avg. volume55,063
Market cap1.398M
Beta (5Y monthly)0.85
PE ratio (TTM)N/A
EPS (TTM)-9.0800
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering

    ACTON, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the closing of its previously announced public offering of 2,692,308 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 2,692,308 shares of common stock at a combined of

  • GlobeNewswire

    Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering

    ACTON, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the pricing of a public offering of 2,692,308 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 2,692,308 shares of common stock at a combined offering price of $1.30 p

  • GlobeNewswire

    Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study)

    This Study performs unique rapid on-site measurements of interleukin-6 (IL-6) and positions Company to move forward with multiple initiatives. ACTON, Mass., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), today announced the initiation of a multicenter clinical study to evaluate the Symphony IL-6 test in sepsis patients (the SYMON study). The Symphony System is designed to address the need for simple, reliable, rapid, near-patient testing